Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECOSPOR IV: SER-109 in Recurrent CDI
NCT03183141Phase 3Completed
- Sponsor
- Seres Therapeutics
- Start
- Oct 2017
- Primary completion
- Apr 2022
- Modality
- Live Biotherapeutic Products
- Countries
- 2
01
Overview
A Phase 3 trial of fecal microbiota, live-brpk in Clostridioides difficile infection (CDI), sponsored by Seres Therapeutics. Started Oct 2017; status: completed.
02
Drugs
fecal microbiota, live-brpk
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT03183141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03183141.